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Abstract
Background: Growth differentiation factor-15 (GDF-15), a biomarker associated with remodeling, 
oxidative stress and inflammation, has been used to stratify heart failure (HF) patients. However, its 
prognostic value in Chinese HF patients is still unknown.
Methods: GDF-15 levels were examined on admission in 272 consecutive HF patients in Beijing 
Hospital (a Chinese tertiary medical center) by a commercial enzyme-linked immunosorbent assay. We 
recorded the incidence of all-cause mortality and/or readmission for HF during a median follow-up 
period of 558 days. Patients were stratified according to the tertiles of GDF-15.
Results: Fifty-three (19.5%) patients died and 103 (37.9%) patients had major adverse cardiac events 
(MACE) which included the composite outcome of all-cause mortality or readmission for HF at the end 
of follow-up. Kaplan-Meier survival curves showed that the third tertile of GDF-15 was associated with 
increased rate of all-cause mortality (compared with the first and second tertiles, log rank p = 0.001 
and 0.001, respectively) or MACE (compared with the first and second tertiles, log rank p = 0.002 and 
p < 0.001, respectively). In addition, multivariate Cox regression model showed that the highest tertile 
of GDF-15 was independently associated with increased risk of all-cause death (hazard ratio = 5.95, 
95% confidence interval 1.88–18.78, p = 0.002) compared with the lowest tertile after adjustment for 
related clinical variables such as age, renal function or N-terminal pro-B-type natriuretic peptide.
Conclusions: Plasma GDF-15 is an independent predictor of all-cause mortality in Chinese patients with 
HF. It may potentially be used to stratify and prognosticate HF patients. (Cardiol J 2018; 25, 2: 245–253)
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Introduction
Heart failure (HF) is a complex syndrome re-
sulted from any structural or functional abnormality 
that leads to the failure of heart to pump enough 
blood to the targeted tissues [1, 2]. Approxi-
mately 4 million people in China [3] have clinically 
symptomatic HF. The prognosis in patients 
with advanced HF is poor, with mortality rate of 
75% at 1 year and virtually no survival at 2 years [4]. 
Thus, early risk stratification in patents with 
HF is important for optimizing clinical decisions 
about treatment and management of end-of-life 
care. In the past few decades, lots of circulat-
ing biomarkers, such as N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) [5], uric acid [6], 
galectin-3 [7], etc., had been used to stratify and 
prognosticate patients with HF [8], among which 
246 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 2
growth differentiation factor-15 (GDF-15) was 
extensively studied [9].
Growth differentiation factor-15, a member of 
transforming growth factor-b cytokine superfam-
ily with a molecular weight of about 28 kDa [10], 
was increasingly expressed in the pathological 
situations associated with inflammation, reactive 
oxygen species and cardiac remodeling, and thus 
might contribute to progression of HF [11, 12]. 
In the last decades, lots of studies indicated 
that elevation of plasma GDF-15 levels could sug-
gest poor prognosis in several cardiovascular dis-
eases, such as acute myocardial infarction [13–15], 
atrial fibrillation [16], and diabetic cardiomyopathy 
[9, 17]. Kempf et al. [13] confirmed that GDF-15 
was an independent predictor of mortality for Cau-
casian population with chronic HF. However, the 
prognostic utility of GDF-15 in Chinese HF patients 
was unclear and the related data were deficient. 
In this study, we evaluated the prognostic value of 
the plasma GDF-15 levels on admission in Chinese 
HF patients.
Methods
Study population and design
Two hundred seventy-two consecutive pa-
tients with an established final diagnosis of HF who 
were admitted to the Department of Cardiology of 
Beijing Hospital (a tertiary educational hospital 
affiliated to National Health and Family Planning 
Commission, Beijing, China) were prospectively 
enrolled from June 2012 to March 2015. Diagnosis 
was established according to the current guidelines 
for the management of HF [1, 2]. In this study, the 
patients were robustly divided into two categories: 
HF with preserved ejection fraction (HFpEF) 
category including those with left ventricular ejec-
tion fraction (LVEF) higher than 45% or HF with 
reduced ejection fraction (HFrEF) category for 
those with LVEF of 45% or less [18, 19].
We collected the blood samples of each patient 
the next morning after admission to hospital and re-
corded the related baseline clinical characteristics 
and in-hospital events. Echocardiography was done 
in echo room of Being Hospital. Standard guideline-
directed medical therapy and optimal management 
were provided according to the latest guidelines for 
the management of HF, unless contraindications.
Inclusion and exclusion criteria
Inpatients definitely diagnosed with HF aged 
more than 18 years were enrolled regardless of 
etiology. The exclusion criteria were: known or 
newly diagnosed malignancy, severe non-cardiac 
comorbidities that would affect the prognosis and 
patient’s disagreement to participate in the study.
Laboratory analyses
Growth differentiation factor-15 concentra-
tion was determined by the enzyme-linked im-
munosorbent assay (ELISA) with a commercial 
human GDF-15 ELISA kits (R&D systems, Min-
nesota, USA) according to the instructions of the 
manufacturer. Routine assays of some other bio-
chemical parameters, such as hemoglobin, albumin, 
creatinine, uric acid, cardiac enzyme profiles, and 
NT-proBNP, etc., were performed in the clini-
cal laboratory of Beijing Hospital. We employed 
a simplified Modification of Diet in Renal Disease 
equation to calculate the estimated glomerular 
filtration rate (eGFR) by the equation: eGFR = 
186.8 × plasma creatinine–1.154 × age –0.203 (× 0.742 
if female patients) [20, 21].
Follow-up and MACE
Patients were subsequently followed up by 
telephone or at the outpatient clinic of Beijing 
Hospital. The primary endpoint was all-cause 
mortality and the secondary composite endpoint 
of major adverse cardiac events (MACE) included 
all-cause mortality and readmission for HF.
Ethical approval
This study was approved by the Ethics Com-
mittee of Being Hospital. Written informed consent 
was obtained from each included patient.
Statistical analysis
Normally distributed data were presented 
as the mean ± standard deviation (SD); whereas 
non-normally distributed data were presented as 
the median (interquartile range [IQR]). Categorical 
data were expressed as percentages. Continuous 
data with normal distribution and homogeneity of 
variance were compared by one-way ANOVA or by 
Kruskal-Wallis test. Categorical data were com-
pared by c2 analysis. Spearman rank correlation was 
used to explore the relationship between GDF-15 
tertiles and related clinical parameters. Logistic re-
gression analyses were done to examine associations 
between variables and all-cause mortality. Receiver 
operating characteristic curve (ROC) was performed 
to statistically assess the sensitivity and specificity 
of GDF-15 measurement and its prognostic utility. 
Cox regression analysis was used to identify predic-
tors of all-cause mortality. Kaplan-Meier survival 
curves and the log-rank test were done according to 
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the time of the MACE. All statistical analyses were 
performed by SPSS version 18.0 (SPSS Inc, Chicago, 
Illinois). Differences were considered significant at 
p values < 0.05 (two-sided).
Results
Baseline clinical characteristics of patients
Overall 272 HF patients with a median age 
of 77 years, of whom 44.1% (120) were female, 
were included in the study. Echocardiographic 
examination was performed in 98.5% (268) of 
patients, of whom, 47% (126) were categorized as 
HFrEF and 53% (142) as HFpEF. For patients re-
ceived  guideline-directed medical therapy; 58.1% 
patients were prescribed angiotensin converting 
enzyme inhibitor (ACEI) or angiotensin receptor 
blocker (ARB), 64.6% spironolactone, and 79.1% 
beta-blocker. 
The median concentration of GDF-15 was 
646.75 ng/mL, with an IQR from 412.48 pg/mL to 
968.03 pg/mL. The patients were stratified into 
tertiles according to GDF-15 concentrations (cut-
off limits 511.35 ng/mL and 839.09 ng/mL): the 
first tertile included values below 511.35 ng/mL; 
the second tertile — from 511.36 ng/mL to 839.09 
ng/mL; the third tertile — above 839.10 ng/mL.
Figure 1 shows that the distribution of GDF-15 
concentration is right-skewed. No significant differ-
ence in GDF-15 concentration was found between 
HFrEF subgroup and HFpEF subgroup (p = 0.09).
Patients with higher GDF-15 levels were charac-
terized by more advanced age (78 years for 2nd tertile 
and 3rd tertile vs. 72 years for 1st tertile) and longer 
hospital stay (the mean duration of hospital stay was 
12 days for 3rd tertile, 11 for 2nd tertile and 10 for 
3rd tertile). The occurrence of coronary artery disease 
(CAD; 70 patients, 77.8%) and diabetes mellitus (DM; 
46 patients, 51.1%) was more frequent in the second 
tertile of GDF-15. Other previously diagnosed condi-
tions including hypertension, obesity, dyslipidemia, 
chronical obstructive pulmonary disease, peripheral 
arterial disease, atrial fibrillation, smoking, and alco-
hol consumption showed no statistically significant 
difference between GDF-15 tertiles (all p values 
> 0.05, Table 1). Spearman’s rank test showed that 
the correlations with age (r = 0.27, p < 0.001) and 
length of stay in hospital (r = 0.18, p = 0.004) were 
very weak. No statistically significant correlations 
were found between GDF-15 levels and occurrence 
of CAD (p = 0.18) or diabetes mellitus (p = 0.54).
The frequency of use of beta-blocker, miner-
alocorticoid receptor antagonists, diuretics and 
digitalis was similar between different GDF-15 
tertiles except that patients in lower tertiles were 
treated with more ACEI or ARB; a weak negative 
correlation was found between use of ACEI or ARB 
and GDF-15 levels (r = –0.25, p < 0.001).
Figure 1. The distribution of baseline growth differentiation factor-15 (GDF-15) levels in this study (n = 272). Median 
(interquartile range): 646.75 (412.48–968.03) pg/mL.
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Higher tertile of GDF-15 was associated with 
more severe renal function impairment (higher 
creatinine, higher uric acid level and lower eGFR), 
worse cardiac function (higher NT-proBNP and 
higher proportion of New York Heart Association 
[NYHA] III–IV) and more severe myocardial injury 
Table 1. Baseline clinical characteristics by tertiles of GDF-15 levels.
Low GDF-15  
tertile (n = 91)
Middle GDF-15  
tertile (n = 91)
High GDF-15  
tertile (n = 90)
P
GDF-15 range [pg/mL] ≤ 511.35 511.36–839.09 ≥ 839.10 –
GDF-15 [pg/mL] 352.4 (264.4–414.0) 647.1 (574.4–743.4) 968.0 (1144.6–1551.4) –
Demographics
Age [years] 72 (59–79) 78 (73–82) 78 (71–82) < 0.01*
Male 55 (60.4%) 45(49.5%) 52 (57.8%) 0.30
BMI [kg/m2] 25.56 ± 4.19 25.66 ± 4.69 24.3 ± 4.36 0.09
History
Hypertension 63 (70%) 74 (82.2%) 65 (72.2%) 0.13
Diabetes mellitus 26 (28.9%) 46(51.1%) 30 (33.3%) 0.005*
Obesity 11 (12.9%) 15 (17.2%) 9 (10.7%) 0.45
Dyslipidemia 64 (71.1%) 56 (62.2%) 50 (56.2%) 0.11
CAD 44 (48.9%) 70 (77.8%) 50 (55.6%) < 0.01*
COPD 7 (7.8%) 9 (10%) 11(12.2%) 0.61
PAD 6(6.7%) 9(10%) 13 (14.4%) 0.18
Atrial fibrillation 41 (45.6%) 35 (38.9%) 48 (53.3%) 0.15
Smoking 34 (39.5%) 32 (37.6%) 39 (43.3%) 0.74
Alcohol 17 (19.5%) 15 (17.6%) 11 (12.2%) 0.39
Length of stay [days] 10 (7–13.25) 11 (7.25–16) 12 (9–18) 0.02*
Medications
ACEI or ARB 65 (73%) 54 (60.7%) 50 (56.2%) < 0.01*
MRA 61 (68.5) 56 (62.9%) 39 (43.3%) 0.63
Beta-blocker 71 (79.8%) 74 (83.1%) 67 (74.4%) 0.35
Diuretics 65 (73%) 74 (81.3%) 75 (83.3%) 0.15
Digitalis 17 (19.1%) 16 (18%) 18 (20.0%) 0.94
Laboratory parameters
Creatinine [µmol/L] 78 (67–89.75) 91 (79–111.75) 106 (87–148) < 0.01*
eGFR [mL/min/1.73 m2] 84.5 (70.7–103.3) 64.4 (50.2–80.3) 49.5 (37.0–73.1) < 0.01*
Uric acid [µmol/L] 366.72 ± 136.83 423.07 ± 109.4 471.11 ± 200.39 < 0.01*
Glucose [mmol/L] 5.4 (4.93–5.98) 5.5 (4.9–6.75) 5.7 (4.8–7.8) 0.39
Albumin [g/L] 41 (39–42) 39 (37–41) 38 (34–40) < 0.01*
Hemoglobin [g/L] 134.98 ± 23.11 122.08 ± 16.54 117.86 ± 25.09 < 0.01*
cTnI [ng/mL] 0.02 (0.01–0.1) 0.04 (0.01–0.13) 0.08 (0.03–0.5) 0.01*
NT-proBNP [pg/mL] 1234 (496.7–2439.5) 1775.5 (937.79–3781.75) 3685 (1691–10796) < 0.01*
Cardiac function
NYHA III–IV 59 (67.8%) 78 (91.8%) 72 (88.9%) < 0.01*
LVEF [%] 40 (28–60) 55 (35–60) 53 (34–60) 0.11
HFpEF 39 (43.3%) 53 (58.9%) 50 (56.8%) 0.08
HFrEF 51 (56.7%) 37 (41.1%) 38 (43.2%) 0.08
*Significant difference. Data are presented as median (interquartile range) or mean ± standard difference according to respective distribution 
type and categorized data are presented as number (percentage); GDF-15 — growth differentiation factor-15; BMI — body mass index; CAD — 
coronary artery disease; COPD — chronic obstructive pulmonary disease; PAD — peripheral arterial disease; ACEI — angiotensin converting 
enzyme inhibitor; ARB — angiotensin receptor blocker; MRA — mineralocorticoid receptor antagonist; eGFR — estimated glomerular filtration 
rate; cTnI — cardiac troponin I; NT-proBNP — N-terminal pro-B-type natriuretic peptide; NYHA — New York Heart Association; LVEF — left 
ventricular ejection fraction; HFpEF — heart failure with preserved ejection fraction; HFrEF — heart failure with reduced ejection fraction
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(cardiac troponin I [cTnI]), whereas albumin and 
hemoglobin concentrations were slightly lower; 
blood glucose, high sensitivity C reactive pro-
tein (hsCRP) and LVEF were similar (Table 1). 
The correlations between GDF-15 levels and cre-
atinine (r = 0.45, p < 0.001), eGFR (r = –0.46, 
p < 0.001), NT-proBNP (r = 0.40, p < 0.001) or 
albumin (r = –0.41, p < 0.001) were moderate; 
the correlations between GDF-15 and uric acid 
(r = 0.24, p < 0.001) or hemoglobin (r = –0.31, 
p < 0.001) were weak; no significant correlation 
was shown between GDF-15 and hsCRP (p = 0.96).
For cTnI, a biomarker of myocardial injury, 
a significant positive correlation was found between 
GDF-15 tertiles and cTnI (r = 0.26, p < 0.001), 
with the median (IQR) concentration of 0.02 (0.01–
–0.1) ng/mL, 0.04 (0.01–0.13) ng/mL and 0.08 
(0.03–0.5) ng/mL for the 1st tertile, 2nd tertile and 
3rd tertile of GDF-15, respectively.
For LVEF, no significant difference (p = 0.11) 
was found between different tertiles of GDF-15; for 
the 1st tertile, 2nd tertile and 3rd tertile, the median 
(IQR) was 40% (28–60%), 55% (35–60%) and 53% 
(34–60%), respectively. The Spearman’s rank corre-
lation analysis showed that there was no significant 
correlation between tertiles of GDF-15 and LVEF 
values (r = 0.08, p = 0.178). Thus, in this population 
with HF, GDF-15 could provide additional prognostic 
information independent of LVEF values.
The proportions of patients with NYHA III–IV 
in the 1st tertile, 2nd tertile and 3rd tertile of GDF-15 
were 67.8% (59), 91.8% (78) and 88.9% (72), 
respectively. Although, higher tertiles of GDF-15 
were associated with a higher proportion of NYHA 
III–IV, no significant correlation (p = 0.125) be-
tween these parameters was found.
Follow-up data and MACE
A total of 24 (8.8%) patients were lost to follow-
up with the median follow-up time of 558 days. The 
primary endpoint occurred in 19.5% (53 patients) 
and the secondary endpoint occurred in 37.9% 
(103 patients). The outcomes by different GDF-15 
tertiles were summarized in Table 2. Patients in 
the third GDF-15 tertile had higher incidence of 
all-cause mortality and/or MACE compared with 
the lower tertiles. The concentration of GDF-15 
in patients with MACE was higher than in those 
without MACE; the medians (IQR) were 858.62 
(636.6–1269.91) pg/mL and 557.48 (361.0–816.97) 
pg/mL, respectively, with p < 0.001. Also, the level 
of GDF-15 in patients with all-cause mortality was 
higher than in those who survived; the medians 
(IQR) were 986.55 (747.68–1493.57) pg/mL and 
577.25 (381.35–846.31) pg/mL, respectively, with 
p < 0.001.
Prognostic significance of GDF-15
Kaplan-Meier survival analysis showed that 
the higher tertile of GDF-15 was associated with 
incremental rate of primary endpoint (compared 
with middle and low tertiles of GDF-15, the log 
rank p = 0.001 and p = 0.001, respectively, Fig. 2A) 
and secondary endpoint (compared with middle and 
low tertiles of GDF-15, the log rank p = 0.002 and 
p < 0.001, respectively, Fig. 2B).
The incidence of primary and secondary end-
points also increased significantly when compared 
the middle tertile with the low tertile of GDF-15 
(the log rank p = 0.02 and p = 0.01, respectively). 
The ability of GDF-15 to discriminate for 
MACE was evaluated by area under the ROC curve 
(AUC). The AUC for GDF-15 was 0.724 (95% con-
fidence interval [CI] 0.662– 0.786, p < 0.001). The 
largest AUC for GDF-15 was obtained at the optimal 
cutoff value of 636.24 pg/mL, with the sensitivity 
of 75.73%, specificity of 65.31%, and Youden index 
= 0.39. The AUC for NT-proBNP was 0.673 (95% 
CI 0.607–0.740, p = 0.00). Pairwise comparison 
of ROC curves between GDF-15 and NT-proBNP 
revealed that the difference between areas was 
0.05 (95% CI –0.025–0.125, p = 0.19, Fig. 3), 
indicating a trend of superiority of GDF-15 versus 
NT-proBNP in predicting the occurrence of MACE 
for Chinese HF patients. When compared the va-
lues of GDF-15 with NT-proBNP in all-cause mor-
tality prediction, we obtained similar results (the 
AUC for GDF-15 was 0.763, Youden index = 0.478, 
Table 2. Outcomes according to tertiles of growth differentiation factor-15 (GDF-15).
Low GDF-15  
tertile (n = 91)
Middle GDF-15  
tertile (n = 91)
High GDF-15  
tertile (n = 90)
P 
All-cause death 4 (4.4%) 16 (17.6%) 33 (36.7%) < 0.001*
MACE 15 (16.5%) 35 (38.5%) 53 (58.9%) < 0.001*
Readmission for HF 11 (12.1%) 24 (26.4%) 34 (37.8%) < 0.001*
*Statistically significant difference; Major adverse cardiac events (MACE) included the composite outcome of all-cause mortality and/or read-
mission for heart failure (HF)
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sensitivity = 81.13%, specificity = 66.67%, cutoff 
value = 710.35 pg/mL, p < 0.001). 
We further tested the associations between 
the related variables that differed significantly 
between tertiles (Table 1) and the risk of all-
cause mortality by the univariate Cox regres-
sion analysis. Advanced age, longer time of stay 
in hospital, previous CAD, deteriorated renal 
function, higher levels of uric acid and NT-pro-
BNP were associated with increased risk of all-
cause mortality (all p values < 0.05, Table 3). 
Conversely, higher level of albumin or hemo-
globin was associated with decreased risk of all-
cause mortality (both p values < 0.05, Table 3). 
With regard to GDF-15, compared with the first 
tertile of GDF-15, high tertile of GDF-15 sig-
nificantly increased the risk of all-cause mortality. 
The hazard ratios (HRs) for all-cause mortality in 
patients in the second and third tertiles were 4.64 
(p = 0.008) and 12.59 (p < 0.001), respectively. 
After including all related variables with p < 0.05 
in Table 3 into multivariate Cox regression model 
by forward likelihood ratio (LR) method, we found 
that the third tertile of GDF-15 was significantly 
associated with increased risk of all-cause mortality 
(HR = 5.95, 95% CI 1.88–18.78, p = 0.002, Table 4) 
Figure 3. Combined receiver-operating characteristic 
curves for growth differentiation factor-15 (GDF-15) and 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
for major adverse cardiac events. Area under the curve 
for GDF-15 is 0.742 (p = 0.00) and for NT-proBNP is 
0.673 (p = 0.00); the difference between areas was 0.05 
(p = 0.19).
Figure 2. A. Kaplan-Meier survival curves for mortality (primary endpoint) according to growth differentiation factor-15 
(GDF-15) tertiles (log rank p = 0.00). A gradual increase in all-cause mortality was shown between GDF-15 tertiles; 
B. Kaplan-Meier survival curves for mortality and/or readmission for heart failure (major adverse cardiac events 
[MACE], secondary endpoint) according to GDF-15 tertiles (log rank p = 0.00). A gradual increase in MACE was shown 
between GDF-15 tertiles.
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when compared with the first tertile, after adjust-
ing for the other variables. While, the second 
tertile became non-significant (HR = 2.54, 95% 
CI 0.78–8.24, p = 0.12, Table 4). The creatinine, 
eGFR, uric acid, albumin, hemoglobin or history 
of CAD became non-significant in the multivariate 
Cox regression model. While, age (HR = 1.04, 
p = 0.002), length of stay in hospital (HR = 1.03, 
p = 0.046), or NT-proBNP (HR per 500 pg/mL = 1.03, 
p = 0.03) still harbored their prognostic value of 
all-cause death. Simultaneously, GDF-15 remained 
significant when it was used as a continues variable. 
The Hosmer-Lemeshow test indicated satisfactory 
calibration for this model (p = 0.86).
Discussion
In present study, we found that elevated levels 
of plasma GDF-15 increased the risk of all-cause 
mortality in Chinese HF patients. After adjustment 
for some other predictors, such as, age, creatinine, 
uric acid, hemoglobin and NT-proBNP, etc., GDF-15 
still exhibited its independent predictive value. 
Additionally, this study also showed that patients 
who died due to any cause or experienced MACE 
had higher levels of GDF-15 compared with the 
events-free counterparts. ROC analysis showed 
that GDF-15 concentration higher than 636.24 pg/ 
/mL was helpful in identifying patients at risk of 
MACE and GDF-15 level higher than 710.35 pg/ 
/mL contributed to predicting all-cause mortality. 
Therefore, this study confirmed the independent 
prognostic utility of GDF-15 in Chinese HF patient.
Till now, this conclusion was consistent with 
some other studies conducted in Caucasian HF pop-
ulation. Valsartan Heart Failure Trial (Val-HeFT) 
[22] proved that baseline GDF-15 concentration 
was independently associated with increased risks 
of all-cause mortality (HR for GDF-15 levels per 
100 ng/L = 1.017) and first morbid events (HR = 
1.02) after adjustment for baseline clinical char-
acteristics and related biochemical variables in all 
HF patients [19]. Kempf et al. [23] also supported 
that GDF-15 could be utilized as a new biomarker 
of the risk of mortality in patients with chronic HF 
which provided prognostic value beyond traditional 
clinical and biochemical variables [20]. Dominguez-
Rodriguez et al. [9] and Foley et al. [24] confirmed 
Table 3. Univariate Cox regression analysis of 
predictors of all-cause mortality at the end of 
follow-up.
Variables HR (95% CI) P
Age [years] 1.07 (1.03–1.11) 0.001*
Length of stay in 
hospital [days]
1.04 (1.01–1.06) 0.002*
Diabetes mellitus 1.34 (0.73–2.46) 0.35
CAD 2.27 (1.15–4.49) 0.02*
ACEI or ARB 0.64 (0.35–1.17) 0.15
Creatinine 
[µmol/L]
1.008 (1.003–1.014) 0.002*
eGFR [mL/min/ 
/1.73 m2]
0.98 (0.97–0.99) 0.002*
Uric acid [µmol/L] 1.003 (1.001–1.005) 0.002*
Albumin [g/L] 0.91 (0.85–0.98) 0.02*
Hemoglobin [g/L] 0.98 (0.97–1) 0.01*
NT-proBNP,  
per 500 pg/mL
1.05 (1.02–1.07) < 0.001*
NYHA III–IV 2.44 (0.83–7.21) 0.11
GDF-15 [pg/mL] – < 0.001*
First tertile 1.0 –
Second tertile 4.64 (1.49–14.48) 0.008*
Third tertile 12.59 (4.23–37.46) < 0.001*
*Statistically significant difference; CI — confidence interval;  
HR — hazard ratio; other abbreviations as in Table 1
Table 4. Multivariate Cox regression analysis of 
predictors of all-cause mortality at the end of 
follow-up.
Variables HR (95% CI) P 
Age [years] 1.05 (1.01–1.10) 0.01*
Length of stay in 
hospital [days]
1.03 (1.00–1.05) 0.046*
CAD – 1.0
Creatinine 
[µmol/L]
– 0.88
eGFR [mL/min/ 
/1.73 m2]
– 0.90
Uric acid [µmol/L] – 0.11
Albumin [g/L] – 0.62
Hemoglobin [g/L] – 0.99
NT-proBNP,  
per 500 pg/mL
1.03 (1.00–1.05) 0.03*
GDF-15 [pg/mL] – 0.003*
First tertile 1.0 –
Second tertile 2.54 (0.78–8.24) 0.12
Third tertile 5.95 (1.88–18.78) 0.002*
*Statistically significant difference. Age, length of stay in hospital, 
NT-proBNP and GDF-15 were associated with increased risk of 
all-cause mortality; heart failure from multivariate Cox regression 
analysis by forward likelihood ratio method. Variables with p < 0.05 
on univariate analysis were shown and included in the multivariable 
model; CI — confidence interval; HR — hazard ratio; other abbre-
viations as in Table 1.
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the role of GDF-15 in predicting morbidity and 
mortality in diabetic cardiomyopathy patients and 
in HF population receiving cardiac synchronization 
therapy, respectively. However, little data could be 
acquired in Asian population. In present study, we 
verified the promising prognostic value of GDF-15 
in Chinese HF patients in both univariate and 
multivariate model. 
The plasma GDF-15 levels will be affected by 
several co-factors. Under normal conditions, GDF-15 
is expressed at low levels in almost all tissues. 
However, in pathological situations, such as HF, 
myocardial remodeling, oxidative stress or pro-
inflammatory state, GDF-15 expression increases 
significantly [12, 16, 25]. In our study, GDF-15 was 
positively correlated with advanced age, deterio-
rated renal function and increased NT-proBNP or 
cTnI; whereas it was negatively correlated with al-
bumin or hemoglobin. Those findings indicated that 
GDF-15 integrated several clinical and biochemical 
markers to provide a comprehensive prognostic 
information for HF.
However, it should be pointed out that GDF-15 
was not a cardiac-specific biomarker. Besides car-
diac myocytes, GDF-15 can also be secreted by 
macrophages [10], vascular endothelial, smooth 
muscle cells [26], and adipocytes [27] in response 
to oxidative stress or chronic inflammation. Just 
like some other non-cardiac-specific biomarkers, 
such as hemoglobin, uric acid, or CRP, GDF-15 
was also able to provide pathophysiological and 
prognostic information for patients with HF. Thus, 
to interpret the value of circulating GDF-15 properly 
and to get an overall prognostic assessment, GDF-15 
levels should be evaluated in conjunction with the 
cardiac-specific markers, such as NT-proBNP.
There were many limitations of this study. First-
ly, the sample size was small and the follow-up time 
was short. Secondly, GDF-15 was measured only one 
time on admission; we did not know how it interacted 
with time and how it fluctuated over time during the 
progression of HF. Thirdly, we enrolled all types of 
HF patients including both HFrEF and HFpEF and 
analyzed data as a homogeneous one, which could 
garble or dilute the prognostic information of GDF-15, 
because different subtype of HF might have distinct 
prognosis. Fourthly, the exactly pathophysiological 
role of chronic elevation of GDF-15 in HF was still 
poorly defined and whether GDF-15 could be used as 
a therapeutic target was yet unknown. Regrettably, 
this study did not answer the question whether 
decrease the level of GDF-15 would improve the 
prognosis of HF. We plan to investigate this issue in 
subsequent research.
Conclusions
Plasma GDF-15 is an independent predictor 
of all-cause mortality in Chinese patients with HF. 
Evaluation of GDF-15 level contributes to stratify 
and prognosticate patients with HF independent 
of conventional risk factors.
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